1. Acehan, D., Jiang, X., Morgan D. G., Heuser, J. E., Wang, X., and Akey, C. W.
(2002). Three-Dimensional Structure of the Apoptosome: Implications for
Assembly, Procaspase-9 Binding, and Activation. Mol. Cell 9(2), 423-432.
2. Ajmal, M., Khan, M. I., Neveling, K., Khan, Y. M., Azam, M., Waheed, N. K., Hamel,
C. P., Ben-Yosef, T., De Baere, E., Koenekoop, R. K., Collin, R. W., Qamar, R.,
and Cremers, F. P. (2014). A missense mutation in the splicing factor gene DHX38
is associated with early-onset retinitis pigmentosa with macular coloboma. J. Med.
Genet. 51(7), 444–448.
3. Anglesio M. S., Carey, M. S., Kobel, M., Mackay, H., Huntsman, D. G., and
Vancouver Ovarian Clear Cell Symposium Speakers. (2011). Clear Cell
Carcinoma of the Ovary: A Report From the First Ovarian Clear Cell Symposium,
June 24th, 2010. Gynecol. Oncol. 121(2), 407-415.
4. Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B.,
and Karni, R. (2013). S6K1 Alternative Splicing Modulates its Oncogenic
Activity and Regulates mTORC1. Cell Rep. 3(1), 103-115.
5. Billen, L. P., Kokoski, C. L., Lovell, J. F., Leber, B., and Andrews, D. W. (2008).
Bcl-XL Inhibit Membrane Permeabilization by Competing with Bax. PLos Biol.
6(6), e147.
6. Bitler, B. G., Wu, S., Park, P. W., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov,
A. V., Vara-Ailor, A., Rauscher, III, F. J., et al. (2018). ARID1A-mutated ovarian
cancers depend on HDAC6 activity. Nat. Cell Biol. 19(8), 962-973.
7. Bode, A. M. and Dong, Z. (2004). Post-Translational Modification of p53 in
Tumorigenesis. Nat. Rev. Cancer 4, 793-805.
63
8. Bracken, A. P., Brien, G. L., and Verrijzer, C. P. (2019). Dangerous Liaisons:
Interplay Between SWI/SNF, NuRD, and Polycomb in Chromatin Regulation and
Cancer. Genes Dev. 33(15-16), 936-959.
9. Chandler, R. L., Damrauer, J. S., Raab, J. R., Schisler, J. C., Wilkerson, M. D., Didion,
J. P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015). Coexistent
ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through
pro-tumorigenic inflammatory cytokine signaling. Nat. Commun. 6, 6118.
10. Chehab, N. H., Malikzay, A., Stavridi, E. S., and Halazonetis, T. D. (1999).
Phosphorylation of Ser-20 Mediates Stabilization of Human p53 in Response to
DNA Damage. Proc. Natl. Acad. Sci. USA 96(24), 13777-13782.
11. Crotzer, D. R., Sun, C. C., Coleman, R. L., Wolf, J. K., Levenback, C. F., and
Gershenson, D. M. (2007). Lack of Effective Systematic Therapy for Recurrent
Clear Cell Carcinoma of the Ovary. Gynecol. Oncol. 105(2), 404-408.
12. Das, S., Anczuków, O., Akerman, M., and Krainer, A. R. (2012). Oncogenic
Splicing Factor SRSF1 is a Critical Transcriptional Target of MYC. Cell Rep. 1(2),
110-117.
13. Dempster, J. M., Rossen, J., Kazachkova, M., Pan, J., Kugener, G., Root, D. E., and
Tsherniak, A. (2019). Extracting Biological Insights from the Project Achilles
Genome-Scale CRISPR Screens in Cancer Cell Lines. Biorxiv 720243.
14. Fraile, J. M., Manchado, E., Lujambio, A., Quesada, V., Campos-Iglesias, D., Webb,
T. R., Lowe, S. W., López-Otín, C., and Freije, J. M. P. (2017). USP39
Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. J. Biol. Chem.
292(10), 4164-4175.
64
15. Hamada, T., Nowak, J. A., and Ogino, S. (2017). PIK3CA mutation and colorectal
cancer precision medicin. Oncotarget. 8(14), 22305-22306.
16. Han, S., Park, J., and Lee, D. H. (2015). Protein DHX38 is a novel inhibitor of
protein phosphatase 4. Anim. Cells Sys. 19(4), 236-244.
17. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 Promotes the Rapid
Degradation of p53. Nature 387(6630), 296-299.
18. Hegele, A., Kamburov, A., Grossmann, A., Sourlis, C., Wowro, S., Weimann, M.,
Will, C. L., Pena, V., Lührmann, R., and Stelzl, U. (2012). Dynamic
Protein-Protein Interaction Wiring of the Human Spliceosome. Mol. Cell 45(4),
567-580.
19. Hemann, M. T. and Lowe, S. W. (2006). The p53-Bcl-2 Connection. Cell Death Diff.
13, 1256-1259.
20. Hsu, H., Xiong, J., and Goeddel, D. (1995). The TNF Receptor 1-Associated Protein
TRADD Signals Cell Death and NF-κB Activation. Cell 81, 495-504.
21. Hsu, T. Y., Simon, L. M., Neill, N., Marcotte, R., Sayad, A., Bland, C. S., Echeverria,
G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015). The Spliceosome is a
Therapeutic Vulnerability in MYC-driven Cancer. Nature 525(7569), 384-388.
22. Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T. P.
(2001).
p300/CBP-mediated p53 acetylation
is
commonly
induced
by
p53-activating agents and inhibited by MDM2. Embo. J. 20(6), 1331-1340.
23. Johnson, J. M., Castle, J., Garrett-Engele, P., Kan, Z., Loerch, P. M., Armour, C. D.,
Santos, R., Schadt, E. E., Stoughton, R., and Shoemaker, D. D. (2003).
Genome-Wide Survey of Human Alternative Pre-mRNA Splicing with Exon
Junction Microarrays. Science 302(5653), 2141-2144.
65
24. Kale, J., Osterlund, E. J., and Andrews, D. W. (2018). BCL-2 Family Proteins:
Changing Partners in the Dance Toward Death. Cell Death Diff. 25, 65-80.
25. Karin, M. (1999). How NF-kB is Activated: the Role of the IkB Kinase (IKK)
Complex. Oncogene 18, 6867-6874.
26. Keenan, A. B., Torre, D., Lachmann, A., Leong, A. K., Wojciechowicz, M. L., Utti,
V., et al. (2019). ChEA3: transcription factor enrichment analysis by orthogonal
omics integration. Nuc. Acids Res. 47(W1), W212-W224.
27. Kim, H., Park, C. K., Lee, S. J., Rha, S. Y., Park, K. H., and Lim, H. Y. (2013).
PIK3CA Mutations in Hepatocellular Carcinoma in Korea. Yonsei Med. J. 54(4),
883-887.
28. Ku, F. C., Wu, R. C., Yang, L. Y. ,Tang, Y. H., Chang, W. Y. Yang, J. E., Wang, C. C.,
Jung, S. M., Lin, C. T., Chang, T. C, et al. (2018). Clear Cell Carcinomas of the
Ovary Have Poorer Outcomes Compared with Serous Carcinomas: Results from a
Single-center Taiwanese Study. J. Formosan Med. Assoc. 117(2), 117-125.
29. Kühnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., and
Kubicka, S. (2000). NF κ B Mediates Apoptosis through Transcriptional
Activation of Fas (CD95) in Adenoviral Hepatitis. JBC 275, 6421-6427.
30. Latif, Z., Chakchouk, I., Schrauwen, I., Lee, K., Santos-Cortez, R., Abbe, I.,
Acharya, A., Jarral, A., Ali, I., Ullah, E., Khan, M. N., Ali, G., Tahir, T. H.,
Bamshad, M. J., Nickerson, D. A., Ahmad, W., Ansar, M., Leal, S. M., and
University of Washington Center for Mendelian Genomics (UWCMG) Study
Group (2018). Confirmation of the Role of DHX38 in the Etiology of Early-Onset
Retinitis Pigmentosa. Ivest. Opthalmol. Vis. Sci. 59(11), 4552–4557.
66
31. Li, W., Chen, Z., Zong, Y., Gong, F., Zhu, Y., Zhu, Y., Lv, J., Zhang, J., Xie, L., Sun,
Y., et al. (2011). PP2A inhibitors induce apoptosis in pancreatic cancer cell line
PANC-1 through persistent phosphorylation of IKKα and sustained activation of
the NF-κB pathway. Cancer Letters 304(2), 117-127.
32. Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S.,
Brown, M., and Liu, X. D. (2014). MAGeCK Enables Robust Identification of
Essential Genes from Genome-Scale CRISPR/Cas9 Knockout Screens. Gen. Biol.
15, 554.
33. Li, X., Zhao, Y., Xia, Q., Zheng, L., Liu, L., Zhao, B., and Jing, S. (2016). Nuclear
Translocation of Annexin 1 Following Oxygen-Glucose Deprivation-reperfusion
Induces Apoptosis by Regulating Bid Expression Via p53 Binding. Cell Death Dis.
7, e2356.
34. Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., and Tamayo,
P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set
collection. Cell Syst. 1(6), 417-425.
35. Lindeonboim, L., Borner, C., and Stein, R. (2001). Bcl-xs can form homodimers and
heterodimers and its apoptotic activity requires localization of Bcl-xs to the
mitochondria and its BH3 and loop domains. Cell Death Diff. 8, 933-942.
36. Liu, P., Wang, Y., and Li, X. (2019). Targeting the Untargetable KRAS in Cancer
Therapy. APSB 9(5), 871-879.
37. Ma, Y., Barnett, T., Chai, L., Yang, J., Alipio, Z., Pei, L., Amin, H. M., Fink, L., Di,
C., Yan, H., and Ward, D. (2006). DEAH-Box Splicing Factor Gene, Prp16
Amplification in Acute Myeloid Leukemia. Blood 108(11), 4779.
67
38. Mabuchi, S., Sugiyama, T., and Kimura, T. (2016). Clear Cell Carcinoma of the
Ovary: Molecular Insights and Future Therapeutic Perspectives. J. Gynecol.
Oncol. 27(3), e31.
39. Matos, P. and Jordan, P. (2006). Rac1, but not Rac1B, Stimulates RelB-mediated
Gene Transcription in Colorectal Cancer Cells. JBC 281, 13724-13732.
40. McCarthy, D. J., Chen, Y., and Smyth, G. K., (2012). Differential expression
analysis of multifactor RNA-Seq experiments with respect to biological variation.
Nuc. Acids Res. 40(10), 4288-4297.
41. McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K.,
Shelton, A. K., Patel, S. D., Limas, J. C., Skinner, K. R., Bash, R. E., et al. (2018).
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not
enhance targeted PI3K inhibition.
42. Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H.,
Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017).
Computational Correction of Copy Number Effect Improves Specificity of
CRIPSR-Cas9 Essentiality Screens in Cancer Cells.
43. Mi, H., Dong, Q., Muruganujan, A., Gaudet, P., Lewis, S., and Thomas, P. D. (2010).
PANTHER version 7: Improved Phylogenetic Trees, Orthologs and Collaboration
with the Gene Ontology Consortium. Nucl. Acids Res. 38, D204-D210.
44. Michael, D. and Oren, M. (2003). The p53-Mdm2 Module and the Ubiquitin System.
Semin. Cancer Biol. 13(1), 49-58.
68
45. Mosele, F., Stefanovska, B., Lusque, A., Dien, T. A., Garberis, I., Droin, N., Le
Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., et al. (2020). Outcome and
Molecular Landscape of Patients with PIK3CA-mutated Metastatic Breast Cancer.
Ann. Onc. 31(3), 377-386.
46. Nagata, S. (1997). Apoptosis by Death Factor. Cell 8(3), 355-365.
47. Ott, M., Robertson, J. D., Gogvadze, V., Zhivotovsky, B., and Orrenius, S. (2002).
Cytochrome c Release from Mitochondria Proceeds by a Two-Step Process.
PNAS 99(3), 1259-1263.
48. Pangallo, J., Kiladjian, J., Cassinat, B., Renneville, A., Taylor, J., Polaski, J. T.,
North, K., Abel-Wahab, O., and Bradley, R. K. (2020). Rare are Private
Spliceosomal Gene Mutations Drive Partial, Complete, and Dual Phenocopies of
Hotspot Alterations. Blood 135(13), 1032-1043.
49. Paronetto, M. P., Achsel, T., Massiello, A., Chalfant, C. E., and Sette. C. (2007). The
RNA-Binding Protein Sam68 Modulates the Alternative Splicing of Bcl-x. J. Cell
Biol. 176(7), 929-939.
50. Rauch, J., Moran-Jones, K., Albrecht, V., Schwarzl, T., Hunter, K., Gires, O., and
Kolch, W. (2011). c-Myc Regulates RNA Splicing of the A-Raf Kinase and its
Activation of the ERK Pathway.Cancer Res. 71(13), 4664-4674.
51. Robinson, M. D., McCarthy, D. J., and Smyth, G. K. (2010). edgeR: a Bioconductor
package for differential expression analysis of digital gene expression data.
Bioinformatics 26(1), 139-140.
52. Samartzis, E. P., Gutsche, K., Dedes, K. J., Fink, D., Stucki, M., and Imesch, P.
(2014). Loss of ARID1A expression sensitizes cancer cells to PI3K- and
AKT-inhibition. Oncotarget5, 5295-5303.
69
53. Sanjana, N. E., Shalem, O., and Zhang, F. (2014). Improved Vectors and
Genome-Wide Libraries for CRISPR Screening. Nat. Methods 11(8), 783-784.
54. Semlow, D. R., Blanco M. R., Walter, N. G., and Staley, J. P. (2016). Spliceosomal
DEAH-Box ATPases Remodel Pre-mRNA to Activate Alternative Splice Sites.
Cell 164(5), 985-998.
55. Sen, N., Hara, M. R., Kornberg, M. D., Cascio, M. B., Bae, B. I., Shahani, N.,
Thomas, B., Dawson, T. M., Dawson, V. L., Snyder, S. H., et al. (2008). Nitric
Oxide-induced Nuclear GAPDH Activates p300/CBP and Mediates Apoptosis.
Nat. Cell Biol. 10, 866-873.
56. Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelson, T.,
Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014). Genome-Scale
CRISPR-Cas9 Knockout Screening in Human Cells. Science 343(6166), 84-87.
57. Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.
C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014). KRAS and YAP1 converge
to regulate EMT and tumor survival. Cell 158(1), 171-184.
58. Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, P. Kapoor, P., Ju, Z., Mo, Q.,
Shih, I., et al. (2015). ARID1A Deficiency Impairs the DNA Damage Checkpoint
and Sensitizes Cells to PARP Inhibitors. Cancer Disc. 5(7), 752-767.
59. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N.,
Settleman, J. Cancer Cell 15(6), 489-500.
60. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillete, M.
A., et al. (2005). Gene set enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles.
70
61. Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Mitsuaki,
S., Sato, I, and Taguchi, K. (2000). Clinical Characteristics of Clear Cell
Carcinoma of the Ovary. Cancer 88(11), 2584-2589.
62. Sun, H., Yang, T., Zang, W., and Wu, S. (2010). Dehydroepiandrosterone-induced
proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT
signaling pathway. J. Endocrinol. 204(3), 311-318.
63. Tang, H., Liu, Y., Wang, X., Guan, L., Chen, W., Jiang, H., and Lu, Y. (2018). Clear
Cell Carcinoma of the Ovary Clinicopathologic Features and Outcomes in a
Chinese Cohort. Medicine. 97(21), e10881.
64. Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N.,
Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2018). COSMIC:
the Catalogue of Somatic Mutations in Cancer. Nuc. Acid Res. 47(D1),
D941-D947.
65. Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R.,
Diemer, K., Muruganujan, A., and Narechania, A. (2003). PANTHER: A Library
of Protein Families and Subfamilies Indexed by Function. Genome Res. 13,
2129-2141.
66. Tseng, C. H., Liu H. L., and Cheng, S. C. (2011). DEAH-box ATPase Prp16 Has
Dual Roles in Remodeling of the Spliceosome in Catalytic Steps. RNA 17,
145-154.
67. Watanabe, R., Ui, A., Kanno, S., Ogiwara, H., Nagase, T., Kohno, T., and Yasui, A.
(2014). SWI/SNF Factors Required for Cellular Resistance to DNA Damage
Include ARID1A and ARID1B and Show Interdependent Protein Stability. Mol.
Cell Pathobiol. 74(9), 2465-2475.
71
68. Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura,
N., Soh, J., Suzuki, M., Witsuba, I. I., Fong, K. M., et al. (2010). PIK3CA
Mutations and Copy Number Gains in Human Lung Cancers. Cancer Res. 68(17),
6913-6921.
69. Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., and Wei, X. (2019). Targeting PI3K in
cancer: mechanisms and advances in clinical trials. Mol. Cancer 18, 26.
70. Zhu, Z., Golay, H. G., and Barbie, D. A. (2014). Targeting Pathways Downstream of
KRAS in Lung Adenocarcinoma. Pharmacogenomics 15(11), 1507-1518.
72
Acknowledgements
First and foremost, I would like to thank Professors Kobayashi Takehiko and Tetsu
Akiyama for their support and encouragement over the course of my studies here at the
University of Tokyo. I would also like to thank Dr. Tomoatsu Hayashi and Dr. Takeaki
Oda for their guidance and mentorship, and together with Dr. Kawasaki Yoshihiro and
Dr. Yamazumi Yusuke for their technical advice and many stimulating discussions. In
addition, I would also like to thank Dr. Suda Sakiko for her assistance with performing
experiments, and Dr. Nagayoshi Yoko and Dr. Kamoshida Yuki for always helping to
give the lab a lively atmosphere, and for many late-night discussions.
I would also like to thank my family and friends for their continuous support
throughout my time here at the University of Tokyo.
Brandon James Cona
73
...
論文の公開元へ
